Kevin Weil, formerly OpenAI’s science chief, launches Warp Sciences with $215 million in new funding to build drug discovery chemistry capabilities for biopharmaceutical customers. Multiple outlets report the effort includes creating a chemistry contract research organization (CRO) in the United States, aimed at supplying molecules to biotech and pharma companies.
The reports add different layers of context. SiliconANGLE emphasizes the company’s launch and its focus on drug discovery chemistry, describing the startup as a U.S.-based CRO. The Next Web adds details attributed to Bloomberg, including that the funding is led by Lightspeed and mentions an indicative valuation figure, as well as the plan to create an automated lab supporting a drug development step that pharma firms have historically outsourced to providers in China.
Overall, both outlets frame the move as a post-OpenAI venture and position Warp Sciences within the broader trend of specialized, outsourced drug development work—shifting focus toward more automated chemistry processes and U.S. supply.
